Target intelligence / Profile preview

TRAF family member-associated NF-kappa-B activator (TANK)

Target
TANK
Molecular classification
Other (Adapter protein), Signal transduction molecule
01

Overview

TRAF family member-associated NF-kappa-B activator (TANK) is a cytoplasmic multifunctional adaptor protein that regulates immune signaling, particularly in pathways leading to the activation or inhibition of NF-kappa-B, a key transcription factor in inflammation, immunity, and cell survival. TANK binds to several TRAF family proteins (TRAF1, TRAF2, TRAF3), often sequestering them and thus inhibiting their downstream signal transduction. It also interacts with TANK-binding kinase 1 (TBK1) and IKBKE, participating in noncanonical NF-kappa-B and antiviral innate immune responses. TANK's activity is context-dependent—it can act both as an inhibitor and coactivator in TRAF-mediated signaling, modulating the activity of TBK1 and the assembly of kinase complexes upstream of NF-kappa-B. Mutations or dysregulation of TANK have been associated with susceptibility to neurological and infectious diseases, and potentially with dysregulated inflammatory states[1][2][3][4].

Other names
ITRAFTRAF-interacting proteinI-TRAFTRAF family member-associated NFKB activatorTRAF2 (historical)TANKTRAF2-interacting proteinI-TRAF[2][3]
02

Mechanism of action

Not applicable for current drug targeting; compound approaches would theoretically modulate immune signaling or NF-kappa-B activation via TANK[1][3].

03

Biological functions

Immune responseSignal transductionRegulation of NF-kappa-B activityNegative regulation of TRAF-mediated pathwaysRegulation of antiviral innate immunity
04

Disease associations

InflammationInfection (e.g., viral infection, antiviral response)Neurodegenerative disease (e.g., Spinocerebellar ataxia 20)Other (Possibly cancer and autoimmunity due to its regulatory role on NF-kappa-B)
05

Safety considerations

Potential risks with targeting TANK could include dysregulation of immune responses, increased susceptibility to infections, or predisposition to inflammatory or immunodeficiency diseases due to its role in NF-kappa-B and antiviral signaling modulation[3].
06

Interacting drugs

None known with direct, clinically approved interactions; the literature does not report any approved drugs that directly target TANK for therapeutic use[3].
07

Biomarkers

No established clinical biomarkers based on TANK status for patient selection or efficacy monitoring[3].

Beyond the preview

Go deeper on TRAF family member-associated NF-kappa-B activator (TANK).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRAF family member-associated NF-kappa-B activator (TANK).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call